Quoin Pharmaceuticals Ltd DRC (QNRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Quoin Pharmaceuticals Ltd DRC, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Quoin Pharmaceuticals Ltd DRC (QNRX) has returned -54.26% so far this year and -15.78% over the past 12 months.

Based on dividend-adjusted daily data since Jul 29, 2016, QNRX's average daily return is -0.08%, while the average monthly return is -5.27%.

Historically, 38% of months were positive and 62% were negative. The best month was Feb 2017 with a return of +112.8%, while the worst month was Nov 2021 at -67.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.

On a daily basis, QNRX closed higher 42% of trading days. The best single day was Aug 3, 2022 with a return of +360.5%, while the worst single day was Aug 5, 2022 at -62.4%.

Quoin Pharmaceuticals Ltd DRC has an annualized alpha of -28.49%, beta of 1.08, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 01, 2016.

• This stock participated in 239.30% of S&P 500 Index downside but only -89.55% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

QNRX ranks 46 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Quoin Pharmaceuticals Ltd DRC (QNRX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Quoin Pharmaceuticals Ltd DRC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Quoin Pharmaceuticals Ltd DRC was 100.00%, occurring on Apr 14, 2025. The portfolio has not yet recovered.

The current Quoin Pharmaceuticals Ltd DRC drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Quoin Pharmaceuticals Ltd DRC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Quoin Pharmaceuticals Ltd DRC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.